SpectraScience Inc., a medical device company using light technologies to detect and diagnose cancers, has acquired the assets of Durham, N.C.-based Oncoscope Inc.
Financial details were not disclosed.
Oncoscope developed a proprietary optical imaging system to detect pre-cancerous tissues using scattered white light. Their first target indication was for Barrett’s Esophagus, a precursor for cancer of the esophagus.
“The Oncoscope technology is the perfect complement to ours,” said Michael Oliver, president and CEO of SpectraScience, in a statement. “Having two complementary technologies allows us to address multiple types of cancers including both esophageal and colon cancer.”
SpectraScience designs, develops and manufactures spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body.